Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials


BACKGROUND To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. RESULTS Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively.Bevacizumab increased the… (More)
DOI: 10.18632/oncotarget.6507


5 Figures and Tables

Slides referencing similar topics